The metabolism of Dexamethasone can be decreased when combined with Idelalisib. The risk or severity of adverse effects can be increased when Denosumab is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Varicella Zoster Vaccine (Live/Attenuated). The metabolism of Dexamethasone can be decreased when combined with Delavirdine. Digitoxin may decrease the cardiotoxic activities of Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Saquinavir. The therapeutic efficacy of Glibornuride can be decreased when used in combination with Dexamethasone. The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Enoxacin. Dexamethasone may increase the hypokalemic activities of Cyclopenthiazide. The serum concentration of Dexamethasone can be increased when it is combined with Stiripentol. The therapeutic efficacy of Calcitriol can be decreased when used in combination with Dexamethasone. The serum concentration of Pravastatin can be increased when it is combined with Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Verapamil. Atracurium besylate may increase the adverse neuromuscular activities of Dexamethasone. The serum concentration of Topotecan can be increased when it is combined with Dexamethasone. The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Dexamethasone. Dexamethasone may increase the hypokalemic activities of Hydrochlorothiazide. The serum concentration of Dexamethasone can be increased when it is combined with Estrone. The serum concentration of Dexamethasone can be increased when it is combined with Ethinyl Estradiol. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Nalidixic Acid. The serum concentration of Dexamethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B. The metabolism of Dexamethasone can be decreased when combined with Isavuconazonium. The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Triptolide is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Salsalate is combined with Dexamethasone. The bioavailability of Dexamethasone can be decreased when combined with Magaldrate. The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Fluvoxamine. The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Balsalazide is combined with Dexamethasone. Dexamethasone may increase the hypokalemic activities of Polythiazide. The risk or severity of adverse effects can be increased when Droxicam is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Benzydamine is combined with Dexamethasone. The serum concentration of Telaprevir can be decreased when it is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Azelastine is combined with Dexamethasone. The serum concentration of Saxagliptin can be decreased when it is combined with Dexamethasone. The therapeutic efficacy of Dexamethasone can be decreased when used in combination with Sarilumab. The risk or severity of adverse effects can be increased when Docetaxel is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Teriflunomide is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Dexamethasone. The serum concentration of Bosutinib can be increased when it is combined with Dexamethasone. Dexamethasone may increase the fluid retaining activities of GLPG-0492. Dexamethasone may decrease the antineoplastic activities of Aldesleukin. The risk or severity of adverse effects can be increased when Semapimod is combined with Dexamethasone. The serum concentration of Vincristine can be decreased when it is combined with Dexamethasone. The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Ambenonium. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Salmonella typhi ty21a live antigen. The serum concentration of Pazopanib can be increased when it is combined with Dexamethasone. The serum concentration of Dexamethasone can be decreased when it is combined with Dabrafenib. The serum concentration of Dexamethasone can be increased when it is combined with Mifepristone. Cholestyramine can cause a decrease in the absorption of Dexamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Nicergoline is combined with Dexamethasone. The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dexamethasone. The serum concentration of Dexamethasone can be increased when it is combined with Aprepitant. The therapeutic efficacy of Exenatide can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Fenoprofen is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Rivastigmine. The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Dexamethasone. The serum concentration of Dexamethasone can be increased when it is combined with Quinestrol. The risk or severity of adverse effects can be increased when Serrapeptase is combined with Dexamethasone. The serum concentration of Prucalopride can be increased when it is combined with Dexamethasone. The serum concentration of Dexamethasone can be increased when it is combined with Ceritinib. The therapeutic efficacy of Miglitol can be decreased when used in combination with Dexamethasone. The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Dexamethasone. Mivacurium may increase the adverse neuromuscular activities of Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Tecemotide. The serum concentration of Dexamethasone can be increased when it is combined with Promestriene. The metabolism of Dexamethasone can be decreased when combined with Lopinavir. The serum concentration of Dexamethasone can be increased when it is combined with Simeprevir. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Prulifloxacin. The serum concentration of Doxorubicin can be increased when it is combined with Dexamethasone. The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Dexamethasone. Dexamethasone may increase the hypokalemic activities of Piretanide. The serum concentration of Fluvastatin can be increased when it is combined with Dexamethasone. The serum concentration of Dexamethasone can be increased when it is combined with Tibolone. The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Masoprocol is combined with Dexamethasone. Cyclophosphamide may increase the cardiotoxic activities of Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Dihydroergotamine. The risk or severity of adverse effects can be increased when Indomethacin is combined with Dexamethasone. Dexamethasone may increase the hypokalemic activities of Metolazone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Grepafloxacin. The risk or severity of adverse effects can be increased when Dexamethasone is combined with SRP 299. The risk or severity of adverse effects can be increased when Adapalene is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Nafamostat is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Minaprine. The serum concentration of Lapatinib can be decreased when it is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Kebuzone is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dexamethasone. The risk or severity of adverse effects can be increased when E-6201 is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Etodolac is combined with Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Posaconazole. Dexamethasone may increase the hypokalemic activities of Bumetanide. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Hepatitis A Vaccine. The metabolism of Dexamethasone can be decreased when combined with Ketoconazole. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated). The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Itraconazole. The risk or severity of adverse effects can be increased when Valdecoxib is combined with Dexamethasone. The serum concentration of Colchicine can be increased when it is combined with Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Ticlopidine. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Flumequine. Dexamethasone may increase the fluid retaining activities of Nandrolone. The therapeutic efficacy of Troglitazone can be decreased when used in combination with Dexamethasone. The metabolism of Dexamethasone can be decreased when combined with Doxycycline. The risk or severity of adverse effects can be increased when Seratrodast is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Gallamine Triethiodide. The serum concentration of Nintedanib can be increased when it is combined with Dexamethasone. The therapeutic efficacy of Repaglinide can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Gatifloxacin. The serum concentration of Dexamethasone can be increased when it is combined with Osimertinib. The serum concentration of Dexamethasone can be decreased when it is combined with Tocilizumab. The risk or severity of adverse effects can be increased when Bucillamine is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Cabergoline is combined with Dexamethasone. Proscillaridin may decrease the cardiotoxic activities of Dexamethasone. Dexamethasone may increase the hypokalemic activities of Etacrynic acid. The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Dexamethasone. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Leflunomide. The risk or severity of adverse effects can be increased when Mesalazine is combined with Dexamethasone. The serum concentration of Dexamethasone can be increased when it is combined with Asparaginase. The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Indoprofen is combined with Dexamethasone. Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dexamethasone. Dexamethasone may increase the hypokalemic activities of Torasemide. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Physostigmine.